Preclinical models for chemotherapy development
Sajina Shakya, Raminderjit Kaur, Lilly J. Speier, Christopher G. Hubert
us (code pays fourni par la source)
0 citations
Elsevier eBooks
Sajina Shakya
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
43Publications signalées
552Citations signalées
1Affiliations récentes
Les institutions déclarées
Les domaines associés
Nuclear Structure and FunctionSarcoma Diagnosis and TreatmentChromatin Remodeling and CancerCancer Cells and MetastasisWound Healing and Treatments
Les publications récentes
STEM-11. TARGETING THE MYC-WDR5 AXIS TO SUPPRESS GLIOBLASTOMA GROWTH AND SELF-RENEWAL
Raminderjit Kaur, Marina Yu. Buyanova, Brandon Nelson, Sajina Shakya et autres
Abstract Glioblastomas (GBMs) are heterogeneous, treatment-resistant tumors driven by cancer stem cells (CSCs) that promote tumor growth, recurrence, and resistance to therapy. The transcription factor Myc, a master regulator of cellular growth and metabolism, is frequently dysregulated in GBM, making it a …
us, it (code pays fourni par la source)
0 citations
Neuro-Oncology
A Material Transfer Agreement between Glioblastoma and Normal Brain Cells
Sajina Shakya, Christopher G. Hubert, Justin Durla Lathia
Tumor cells communicate with normal cells in various ways, typically leading to the exploitation of resources of the normal cells by tumor cells for their benefit. In this issue, Mangena and colleagues use three-dimensional organoid models to show the transfer of GFP …
us (code pays fourni par la source)
1 citation
Cancer Discovery
List of contributors
Rolla Abu-Arja, Jenny K. Adamski, Manish Kumar Aghi, Manmeet Singh Ahluwalia et autres
us, gb, il, ca, de, ph, ge (code pays fourni par la source)
0 citations
Elsevier eBooks
Effects of a social network intervention on HIV seroconversion among people who inject drugs in Ukraine: moderation by network gender composition
John Mark Wiginton, Robert E. Booth, Laramie R. Smith, Sajina Shakya et autres
BACKGROUND: Women who inject drugs in Ukraine are disproportionately burdened by HIV. To help address the needs of this population, a greater understanding of how interventions may uniquely benefit women who inject drugs is needed. METHODS: Data come from a randomized controlled …
us (code pays fourni par la source)
2 citations
Harm Reduction Journal
STEM-24. WDR5 REPRESENTS A THERAPEUTICALLY EXPLOITABLE TARGET FOR CANCER STEM CELLS IN GLIOBLASTOMA
Kelly Mitchell, Samuel A. Sprowls, Sajina Shakya, Sonali Arora et autres
Abstract Glioblastomas (GBMs) are heterogeneous, treatment-resistant tumors that are driven by populations of cancer stem cells (CSCs). In this study, we perform an epigenetic-focused functional genomics screen in GBM organoids and identify WDR5 as an essential epigenetic regulator in the SOX2-enriched, therapy …
us (code pays fourni par la source)
0 citations
Neuro-Oncology
361 WDR5 represents a therapeutically exploitable target for cancer stem cells in glioblastoma
Christopher G. Hubert, Kelly Mitchell, Samuel A. Sprowls, Sajina Shakya et autres
OBJECTIVES/GOALS: Glioblastomas (GBMs) are heterogeneous, treatment-resistant tumors that are driven by populations of cancer stem cells (CSCs). In this study, we perform an epigenetic-focused functional genomics screen in GBM organoids and identify WDR5 as an essential epigenetic regulator in the SOX2-enriched, therapy …
us (code pays fourni par la source)
0 citations
Journal of Clinical and Translational Science
Data from VRK1 Is a Synthetic–Lethal Target in VRK2-Deficient Glioblastoma
Julie A. Shields, Samuel R. Meier, Madhavi L. Bandi, Erin E. Mulkearns-Hubert et autres
Abstract Synthetic lethality is a genetic interaction that results in cell death when two genetic deficiencies co-occur but not when either deficiency occurs alone, which can be co-opted for cancer therapeutics. Pairs of paralog genes are among the most straightforward potential synthetic–lethal …
us (code pays fourni par la source)
0 citations
Supplementary Data from VRK1 Is a Synthetic–Lethal Target in VRK2-Deficient Glioblastoma
Julie A. Shields, Samuel R. Meier, Madhavi L. Bandi, Erin E. Mulkearns-Hubert et autres
Supplementary Data from VRK1 Is a Synthetic–Lethal Target in VRK2-Deficient Glioblastoma
0 citations
Supplementary Figure from VRK1 Is a Synthetic–Lethal Target in VRK2-Deficient Glioblastoma
Julie A. Shields, Samuel R. Meier, Madhavi L. Bandi, Erin E. Mulkearns-Hubert et autres
Supplementary Figure from VRK1 Is a Synthetic–Lethal Target in VRK2-Deficient Glioblastoma
0 citations
Supplementary Data from VRK1 Is a Synthetic–Lethal Target in VRK2-Deficient Glioblastoma
Julie A. Shields, Samuel R. Meier, Madhavi L. Bandi, Erin E. Mulkearns-Hubert et autres
Supplementary Data from VRK1 Is a Synthetic–Lethal Target in VRK2-Deficient Glioblastoma
0 citations
Supplementary Data from VRK1 Is a Synthetic–Lethal Target in VRK2-Deficient Glioblastoma
Julie A. Shields, Samuel R. Meier, Madhavi L. Bandi, Erin E. Mulkearns-Hubert et autres
Supplementary Data from VRK1 Is a Synthetic–Lethal Target in VRK2-Deficient Glioblastoma
0 citations
BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.